Recursion Pharmaceuticals uses AI to expedite the laborious process of developing drugs. The company could benefit from industry-wide regulatory changes as well as its own clinical progress. However, ...

Recursion Pharmaceuticals (NASDAQ: RXRX), a biotech focused on artificial intelligence (AI), became a publicly traded company in 2021 -- a time when AI did not grab nearly as much attention (if any at ...

In this article, we will be taking a look at the Top 10 AI-Powered Biotech Stocks to Buy Now. Recursion Pharmaceuticals, Inc. is one of them. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX), a ...

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the Best Penny Stocks to Buy with the Highest Upside Potential. On September 10, Gil Blum from Needham reiterated a Buy rating on Recursion ...

How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Recursion Pharmaceuticals (RXRX) closed at $4.77 in the latest trading session, marking a -1.24% move from the prior day. This change lagged the S&P 500's 0.47% gain on the day. Meanwhile, the Dow ...

In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...